UBS/CALL/MODERNA/140.001/0.1/20.12.24 | Market Closed - Swiss Exchange 11:20:00 2024-06-05 EDT | ||
| 2.75 CHF | +17.02% |
|
| Current month | +6.18% | ||
| 1 month | +102.21% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-05 | 2.75 | +17.02% |
| 24-06-04 | 2.35 | -12.31% |
| 24-06-03 | 2.68 | +3.47% |
| 24-05-31 | 2.59 | +7.47% |
| 24-05-30 | 2.41 | -0.82% |
Delayed Quote Swiss Exchange
Last update June 05, 2024 at 11:20 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | UBS |
| PMRNCU | |
| ISIN | CH1310060905 |
| Date issued | 2023-12-27 |
| Strike | 140 $ |
| Maturity | 2024-12-20 (198 Days) |
| Parity | 10 : 1 |
| Emission price | 0.9 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 3.96 CHF |
|---|---|
| Lowest since issue | 0.41 CHF |
| Spread | 0.05 CHF |
| Spread % | 1.79% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
145.3
USD
Average target price
142.8
USD
Spread / Average Target
-1.74%
- Stock Market
- Warrants
- PMRNCU Warrant
